Ashish Shiwlani
Adv. Know. Base. Syst. Data Sci. Cyber., 2 (3):412-442
Ashish Shiwlani : Illinois Institute of Technology
Article History: Received on: 21-Sep-25, Accepted on: 17-Dec-25, Published on: 24-Dec-25
Corresponding Author: Ashish Shiwlani
Email: shiwlaniashish@gmail.com
Citation: Sooraj Kumar, Dr. Kajol kumara, Dr. Roma Lohano, Sunil Kumar, Zeib Jahangir, Pawan Kumar, Ashish Shiwlani. (2025). AI-Augmented Precision Lifestyle Interventions for Type 2 Diabetes Remission: A Systematic Review. Adv. Know. Base. Syst. Data Sci. Cyber., 2 (3 ):412-442
Background Type 2 diabetes mellitus (T2DM) is a major global health challenge.
While lifestyle interventions can induce remission, their effectiveness is
often constrained by inter-individual variability. Artificial intelligence (AI)
and machine learning (ML) offer possibilities for precision lifestyle medicine
by tailoring interventions to individual patient profiles.
Objective To synthesize evidence on AI- and ML-enhanced lifestyle interventions
targeting remission of T2DM, with emphasis on algorithms, data sources, and
personalization strategies.
Methods Systematic searches of PubMed, Embase, Scopus, IEEE Xplore, and Web of
Science (2015–August 2025) identified studies using AI/ML in lifestyle-focused
T2DM interventions. From 3,220 records, 100 studies met inclusion criteria.
Eligible studies involved adults with T2DM, reported remission or glycemic
outcomes, and applied AI to personalize lifestyle programs. Data were
synthesized narratively according to PRISMA 2020 guidelines.
Results Studies span diverse geographies, with interventions delivered via
mobile apps, conversational agents, decision support systems, and digital
twins. AI methods included supervised models (random forests, gradient
boosting, support vector machines) for prediction, convolutional neural
networks for remission forecasting in surgical cohorts, recurrent neural
networks for glucose forecasting, clustering for phenotype stratification, and
reinforcement learning for adaptive insulin titration and multimorbidity
management. Data inputs ranged from continuous glucose monitoring and wearables
to dietary logs, electronic health records, and multi-omics. Outcomes were
favorable, with remission rates exceeding 70% in some digital twin and
subtype-based interventions, alongside significant HbA1c reduction, weight
loss, and medication tapering.
Conclusion AI and ML can transform T2DM care by enabling adaptive, precision
interventions for remission. Future work should emphasize large-scale trials,
explainable algorithms, and equitable deployment to ensure sustainable
real-world impact.